Although Immunotherapy has emerged as an efficient treatment in lung carcinoma, merely a subset of lung adenocarcinoma (LUAD) patients could be benefited from it. Increasing evidence revealed that tumor immune cell infiltrating (ICI) in the tumor microenvironment (TME) is highly related to patient prognosis and characteristics of the tumor. Thus far, the immune cell infiltration patterns of LUAD remain unclear. Herein, ESTIMATE and CIBERSORT algorithms were conducted to characterize the ICI patterns of 1155 patients with LUAD. Three ICI subtypes were determined, and the ICI score was constructed by performing PCA. A high ICI score group referred to increased activation of the signaling pathways related to immune activation and drug metabolism, reduced tumor mutation burden (TMB), as well as significantly higher expression levels of CTLA-4, PD-1, LAG3, and immune-activation-related genes. Patients who had high ICI scores showed better overall survival (OS) compared to those with low ICI scores, irrespective of TMB status. This study demonstrated that ICI scores serve as an original and effective indicator for independent prognostic prediction as well as customized immune therapy of LUAD. Establishing the ICI patterns of a larger patient population will extend our knowledg of TME, and it may facilitate the development of immunotherapies specific to LUAD.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891687PMC
http://dx.doi.org/10.1016/j.heliyon.2025.e42720DOI Listing

Publication Analysis

Top Keywords

immune cell
12
ici scores
12
ici
9
cell infiltration
8
infiltration patterns
8
lung adenocarcinoma
8
tumor immune
8
ici patterns
8
ici score
8
high ici
8

Similar Publications

Background: Cervical adenocarcinoma (ADC) is more aggressive compared to other types of cervical cancer (CC), such as squamous cell carcinoma (SCC). The tumor immune microenvironment (TIME) and tumor heterogeneity are recognized as pivotal factors in cancer progression and therapy. However, the disparities in TIME and heterogeneity between ADC and SCC are poorly understood.

View Article and Find Full Text PDF

Advancing Tumor Microenvironment Analysis: A Fluorescence Nanosystem for Caspase-1 Monitoring and Synergistic Therapy.

Anal Chem

March 2025

College of Chemistry, Jilin Province Research Center for Engineering and Technology of Spectral Analytical Instruments, Jilin University, Qianjin Street 2699, Changchun 130012, China.

The lack of precise, real-time analytical tools for monitoring tumor microenvironment changes during treatment hinders advancements in integrated diagnostic and therapeutic platforms. Traditional caspase-3 monitoring strategies are limited by their inability to address drug resistance and newly discovered apoptotic pathways, leading to reduced accuracy and practicality. To overcome these limitations, we developed a fluorescence-based "Trojan horse" nanosystem, PFpR@CM, featuring high-sensitivity Caspase-1 detection, tumor-targeted delivery, and photothermal therapy.

View Article and Find Full Text PDF

Background: Early diagnosis and intervention are essential for improving the prognosis and survival of gastric cancer (GC) patients. However, specific biomarkers for early GC diagnosis are still unavailable.

Methods: Data-independent acquisition (DIA) proteomics was employed to identify differentially expressed proteins (DEPs) between GC and adjacent non-tumor tissues.

View Article and Find Full Text PDF

Background: The development of immunotherapy has led to a paradigm shift in the treatment of malignant tumors. Immune checkpoint inhibitors (ICIs) function by blocking the receptors and ligands of T cells from binding one another, empowering them to target and attack cancer cells. ICIs along with other immunotherapy treatments, have seen a significant increase in usage in recent years.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!